FOR IMMEDIATE RELEASE
November 5, 2012

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

LGM Pharma Attends CPhI Worldwide in Madrid

NASHVILLE, Tennessee - LGM Pharma attended the CPhI Worldwide 2012 event in Madrid, Spain on October 9-12. The event featured over 29,000 attendees from 133 countries and 2,200 exhibitors. Attendees ranged from the entire spectrum of the pharmaceutical industry, including API manufacturers and biopharmaceutical firms, to contract research organizations (CRO) and contract research and manufacturing service (CRAMS) organizations. LGM Pharma held several face-to-face, highly targeted meetings at the show, to identify business opportunities and cultivate potential partnerships.

CPhI Worldwide is one of the world’s leading pharmaceutical networking events. "CPhI provides an efficient and effective platform to actively do business, and stay informed about the latest industry trends." explains Mendy Schurder, COO of LGM Pharma, a leading supplier of active pharmaceutical ingredients (APIs) to global pharmaceutical firms, "As a further reflection of growth in the company, we anticipate continued participation in similar trade shows for the drug industry, including the API China Fair, Informex USA and DCAT Week."

About LGM Pharma
LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. Their corporate offices are located in Nashville, Tennessee.

###

FOR IMMEDIATE RELEASE
June 22, 2012

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

LGM Pharma Attended the BIO International Convention in Boston, USA

NASHVILLE, Tennessee - LGM Pharma was represented at the International Bio Conference in Boston June 18 - 21 by our sales team, who met with several clients and prospective clients.

The Company successfully expanded its network of custom manufacturing partners, most notably in biologics, which was a dominant theme at the conference.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

About LGM Pharma
LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. Their corporate offices are located in Nashville, Tennessee.

###

FOR IMMEDIATE RELEASE
April 17, 2012

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

New Drugs and Therapies at the Forefront of Treatment for Acute Lymphoblastic Leukemia

Local firm supplies active pharmaceutical ingredients to various global pharmaceutical companies who develop new therapies.

BOCA RATON, Florida - Promising news for families with children suffering from acute lymphoblastic leukemia, or ALL, was recently published in Reuters Health. Results were released from a study conducted at the University of Colorado School of Medicine and Children's Hospital, which revealed significant gains in the fight against childhood leukemia have been made.

Data gleaned from this study showed that of 20,000 babies, children and adolescents who had ALL, the survival rate of at least five years after the initial diagnosis increased, from 84 percent in the early 1990's to 90 percent a decade later. This research is hopeful, especially considering the fact that 98 percent of childhood leukemias are classified as acute lymphocytic leukemia. In addition, 25 percent of all childhood cancers are leukemia, which amount to roughly 2,200 American children each year.

According to Mendy Schurder, COO of LGM Pharma, a leading supplier of active pharmaceutical ingredients (APIs) to global pharmaceutical firms, "LGM Pharma supplies APIs to University and research companies who develop new therapies and drugs to help combat this disease. The exploration of personalized medical care through the use of Theranostics—diagnostics that are closely tied to a specific drug treatment—is poised to become the next wave of pharmaceutical revelations and customized care."

Researchers also received encouraging news on March 22, 2012, with the information that the novel drug to treat acute lymphoblastic leukemia, known as Marqibo won an FDA panel vote. Of the 65 patients in the single-arm study, 20 percent experienced a complete or nearly complete response, with a median duration of 5.4 months, and an overall 7.7 month survival rate. This news is the latest in several galvanizing reports released regarding new and innovative treatments for acute lymphoblastic leukemia.

"As a cancer of the bone marrow and blood, the child with leukemia has bone marrow that begins to make blood cells that don't mature properly," explains Robert Hoppes, Director of Sales "These immature cells continue to reproduce, thus crowding out the healthy cells. Effective treatment is not only crucial, it is also completely within reach for scientists today. Only fifty years ago childhood leukemia was considered an incurable disease, and literally all children affected by it did not survive."

About LGM Pharma
LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

###

FOR IMMEDIATE RELEASE
February 14, 2012

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

LGM Pharma to Exhibit at Informex Conference

BOCA RATON, Florida - LGM Pharma, a supplier of active pharmaceutical ingredients (APIs), announced that it is exhibiting at the Informex 2012 conference to be held at the Morial Convention Center in New Orleans, Louisiana. LGM Pharma will be exhibiting from February 14-17, 2012 in Booth #706. The Informex audience boasts innovative scientists, heads of research and development, corporate strategists, and captains of industry. The event will feature more than 500 exhibitors and more than 4,000 attendees.

Informex is the premier trade show event for the fine and performance chemical industry. It is returning to New Orleans in 2012 to once again offer exhibitors and attendees a direct view of what is happening domestically and internationally across the key players in fine and specialty chemical companies.

According to Mendy Schurder, COO of LGM Pharma, “The global marketplace has changed. New industry standards and approaches have drastically re-shaped the landscape of doing business in the specialty and fine chemicals sectors. It has become clear that one of the keys to success in global business is to solidify relationships both domestically and internationally.”

Informex brings together serious buyers and sellers of chemicals, biologics, chemical technologies and related services. It is the global meeting place to efficiently showcase as well as learn about the capabilities of high-value, high quality fine, specialty and custom chemical manufacturers, from pilot to commercial scale.

About LGM Pharma
LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

###

FOR IMMEDIATE RELEASE
January 4, 2012

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

LGM Pharma Joins the Society of Chemical Manufacturers and Affiliates

BOCA RATON, Florida - LGM Pharma announced today its membership to the Society of Chemical Manufacturers and Affiliates (SOCMA), the leading international trade association representing the batch, custom and specialty chemical industry. The Washington-based group supports chemical manufacturers with commercial and networking opportunities, advocates for the passage of rational laws and regulation, and works to increase public confidence in the industry.

“LGM Pharma has always had a commitment to being a good corporate citizen and member of the batch chemical manufacturing community, so joining SOCMA was a natural fit,” said Leah Chitrik, CEO of LGM Pharma. “Our new membership in SOCMA will help us grow our business and keep up-to-date on the latest issues and best practices for the industry. This membership will benefit not only LGM Pharma, but also our customers and community.”

“We are pleased to welcome LGM Pharma as our newest member company and look forward to their active participation in the organization,” said SOCMA President and CEO Lawrence D. Sloan.

About LGM Pharma
LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

About SOCMA
SOCMA is the only U.S. based trade association dedicated solely to the batch, custom and specialty chemical industry. Since 1921, the organization has represented a diverse membership of small, medium and large chemical companies and has a global membership of more than 200 companies. For more information on their services and products, please visit www.socma.com.

###

FOR IMMEDIATE RELEASE
December 14, 2011

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

LGM Pharma Showcased by Palm Beach County’s Business Development Board

BOCA RATON, Florida - LGM Pharma, a supplier of active pharmaceutical ingredients (APIs), was invited to participate in an industry spotlight during the recent Life Sciences Industry Focus Luncheon by the Business Development Board in Palm Beach County.  

The invitation which was issued to a select number of Palm Beach County life sciences companies was intended to showcase new and innovative life sciences companies that have started or moved to Palm Beach County since the Scripps relocation. This showcase demonstrated to the business community and elected officials in Palm Beach County the return on the investment from establishing and building a life sciences cluster in Palm Beach County.

LGM Pharma recently moved into a new corporate headquarters in Boca Raton. The move was part of the firm’s long-term plan for steady and careful growth, meeting both their current needs as well as accommodating future development.

According to Mendy Schurder, COO of LGM Pharma, “For LGM Pharma, Palm Beach County has everything our company needs to grow, including a healthy business climate which is home to thousands of life science companies and research organizations employing thousands of Floridians such as myself. Along with my fellow co-workers, we are all happily living and raising our families in the surrounding Boca/Delray/Boynton Beach neighborhoods. We all immensely enjoy the incredible natural resources we have here, such as the ocean, wildlife, and of course the great climate.”

Palm Beach County is the heart of Florida’s emerging nationally ranked bioscience and biotech center. Forbes.com recently ranked Palm Beach County #3 on its list of “Hotbeds of Tomorrow’s Technology.”

The Business Development Board states that with more than 150 biotechnology companies in Palm Beach County, the area continues to be a global leader in the discovery and advancement of drugs and pharmaceuticals, medical devices and equipment, as well as in research and development.

Palm Beach County’s institutes of higher education, research parks, incubators and technology transfer center create an environment where biotech companies thrive. Progressive business policies, quality workforce and a positive economic climate encourage innovative partnerships and capital investment that enables companies to compete globally.

About LGM Pharma
LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

###

FOR IMMEDIATE RELEASE
December 14, 2011

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

Drug Development Boot Camp Holds True to its Name

BOCA RATON, Florida - Robert Hoppes, Director of Sales for R&D for LGM Pharma, a supplier of active pharmaceutical ingredients (APIs) in Boca Raton, Florida, recently attended the Drug Development Boot Camp offered by Speid & Associates, Inc. and Harvard University’s Office of Technology Development.

This intensive two-day course for Biotech and Pharma company executives provided an opportunity for participants to obtain a hands-on insight into the drug development process from drug discovery to regulatory approval. The program presented a unique interactive platform to engage with industry colleagues from a variety of disciplines on each step of the drug development process.  The drug development boot camp also presented a good forum to discuss the changing landscape of the pharmaceutical industry.  Much of the dialogue was about the shift to specialization rather than having all aspects of the development process done in-house by one company.  With all of the downsizing and constricting of drug pipelines, more emphasis is being placed on outsourcing expertise and increasing collaboration.

According to Mr. Hoppes, “This was a unique opportunity to be totally immersed in the drug development process and to mix with a fascinating group of professionals that have proven themselves by bringing drugs to market.”

About LGM Pharma
LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

###

FOR IMMEDIATE RELEASE
December 5, 2011

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

LGM Pharma Receives Certification from the International Organization for Standardization

BOCA RATON, Florida—LGM Pharma, a supplier of active pharmaceutical ingredients (APIs) in Boca Raton, Florida, has received certification from the International Organization for Standardization (ISO), a group that addresses quality management. Click here to view the ISO 9001:2008 certificate.

ISO 9001:2008 is the benchmark that provides a set of standardized requirements for a quality management system, regardless of what the user organization does, its size, or whether it is in the private, or public sector. It is the only standard against which organizations can be certified.

The standards are about assisting organizations to achieve customer satisfaction. As customer needs and expectations are changing, the effective organizations are driven to continually improve their products, services and processes.

According to Robert Hoppes, Director of Sales for R&D, “LGM Pharma is committed to our clients’ success by providing rare and novel active pharmaceutical ingredients of the highest quality for their drug development and research projects.  Our goal is to exceed our clients’ expectations by ensuring our products’ quality is consistently of the highest standards, ensure on-time delivery, provide technical and regulatory assistance and empower our employees to promote continuous improvement of our systems.”

About LGM Pharma
LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

###

FOR IMMEDIATE RELEASE
November 28, 2011

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

LGM Pharma Attends CPhI Conference in Germany

BOCA RATON, Florida—LGM Pharma, a supplier of active pharmaceutical ingredients (APIs), recently attended the CPhI Worldwide Conference in Frankfurt, Germany.  The conference agenda tackled the most timely and business critical issues facing the pharmaceutical industry today.

According to Mendy Schurder, COO of LGM Pharma, “By attending a CPhI conference, we had the opportunity to gather the latest market trends, explore key case study insights and benefit from exceptional networking opportunities all under one roof.”   

During the conference, representatives of LGM Pharma met with strategic manufacturers to discuss involvement in the development of commercial products.

“Now that LGM Pharma has gained a certain reputation, we received positive feedback from manufacturers who were enthusiastic about working with us,” continued Mr. Schurder.  “We had a number of successful meetings with clients and brought them key projects.  We were delighted with their interest in working with us.”

About LGM Pharma
LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

About CPhI Worldwide
CPhI Worldwide is a unique event for the global Pharma community.  Exhibitors have been benefiting from its unequalled business and networking opportunities for more than 20 years. 

###

FOR IMMEDIATE RELEASE
October 6, 2011

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

LGM Pharma Works with Overseas Providers to Assure Quality Control of Pharmaceuticals

BOCA RATON, Florida—As is the case in almost every industry, pharmaceutical manufacturing is becoming an increasingly global business. Between 2001 and 2008, the number of drugs produced outside the U.S. doubled. While this certainly reduces production costs for manufacturers and potentially reduces the costs that consumers pay for pharmaceuticals, the safety of the drugs may be sacrificed in the process. When the manufacturers outsource their production, the level of actual control for both the manufacturer and the Food and Drug Administration (FDA) is effectively reduced.

In today’s competitive drug development market, having a reliable and knowledgeable supply chain can make the difference in a project’s success.  LGM Pharma, a supplier of active pharmaceutical ingredients (APIs) in Boca Raton, Florida, specializes in providing full sourcing options and support for the widest range of rare and new APIs in the research and development community.

According to Mendy Schurder, COO of LGM Pharma, “Depending on a client’s regulatory needs, LGM Pharma can provide APIs with full regulatory support from many global manufacturers who are approved by the leading health authorities, such as the Food and Drug Administration (US), European Directorate for the Quality of Medicines & Healthcare, Therapeutic Goods Administration (Australia), and the Medicines and Healthcare products Regulatory Agency (UK).  We also work with the FDA and US Pharmacopeia providing ingredients for testing and comparison.”

Over the past couple of decades, the pharmaceutical supply chain has become increasingly complex, and medications may pass through many facilities before reaching their final destination in the United States.  In fact, as much as 80 percent of active pharmaceutical ingredients in products sold in this country now come from foreign sources. With $2 trillion worth of products entering the United States, the FDA faces a host of challenges—such as language, laws, and culture—in keeping Americans safe from adulterated drugs manufactured in other countries.

Overseas manufacturing has brought benefits in terms of lowering the cost of producing APIs and excipients used in US drug products, and of many finished drugs sold the US. The dark side of the arrangement, and the one that worries consumers, manufacturers, and regulatory agencies, is that quality control becomes very difficult when supply chains involve the routing of thousands of products through manufacturers, packagers, and distributers dispersed around the world.

“Our staff perform factory audits around the world for our clients to evaluate the facility for quality,” says Robert Hoppes, LGM Pharma Sales Director “We review the processes, regulations, and documentation.  The LGM Pharma team has visited sites in South Korea, Germany and China, among others, to ensure that the facilities are qualified to produce products that are safe and effective.”

LGM Pharma will shortly be undergoing their first audit for certification from the International Organization for Standardization (ISO), a group that addresses quality management. ISO 9001:2008 is the benchmark that provides a set of standardized requirements for a quality management system, regardless of what the user organization does, its size, or whether it is in the private, or public sector. It is the only standard against which organizations can be certified.

Mr. Schurder concludes, “The quality of pharmaceuticals is a global concern, and the lack of reliable drug quality assurance systems in many developing countries often contributes to the devastation of diseases. Our goal is to contribute to a safe, high-quality supply of medicines.  While today’s realities have necessitated changes in our approach, we are eager to meet the challenge.”

About LGM Pharma
LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

###

FOR IMMEDIATE RELEASE
Septemeber 15, 2011

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

Reports Show Superbug Strains of Drug Resistant Gonorrhea on the Rise

LGM Pharma has forged partnerships with its clients to supply products for research and development needs.

BOCA RATON, Florida:  Gonorrhea, a sexually transmitted disease (STD) caused by the bacterium Neisseria Gonorrhoeae, is a very common infectious disease among the sexually active young adults and teens. The Center for Disease Control and Prevention (CDC) estimates that more than 700,000 persons in the U.S. acquire the infection yearly. Unlike HIV, exchange of body fluids does not necessarily have to occur for the bacterium to get transmitted.

Six years ago, another group of antibiotics, fluoroquinolones, was crossed off the list of recommended drugs for the treatment of uncomplicated gonorrhea in Oregon and California due to widespread resistance to it. In the last decade, there have been a growing number of cases of gonorrhea that are resistant to Cefixime that is taken orally, and the injectable ceftriaxone.

These chilling reports have alerted LGM Pharma, a Boca Raton supplier of active pharmaceutical ingredients, and its partners to the gravity of the emerging “superbug” resistance. Rather than panic, the company and its clients have chosen to work closely together to combat the superbug. The unique partnerships forged by LGM Pharma with its clients currently in the forefront of antibiotic resistance research have put them in a pivotal position to supply tailored products for their research and development needs.

The disease is serious, and the propensity of some of its strains to be antibiotic resistant dooms the patient to a lifetime of incurable infection that spreads to other organs. The pharmaceutical industry, especially LGM Pharma, is taking action along with the medical community’s fight against the superbug.

“The company is well aware of what’s happening in the world of medical research and development,” adds Mendy Schurder, COO of LGM Pharma. “These reports might seem inconsequential but these antibiotic resistant strains are of great concern and warrant significant attention and resources to make certain the necessary therapies are available when the need arises.”

About LGM Pharma

LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

###

FOR IMMEDIATE RELEASE
July 15, 2011

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

LGM Pharma Moves Corporate Headquarters to New Location

BOCA RATON, Florida — LGM Pharma, a leading supplier of active pharmaceutical ingredients to various global pharmaceutical firms, announced its recent move into a new corporate headquarters in Boca Raton, Florida. The move is part of the firm’s long-term plan for steady and careful growth, meeting both their current needs as well as accommodating future development.

The company also paid careful consideration to ways that would improve the at-work experience for their employees, allowing them to be more efficient and productive, through space planning and collaborative workspaces. 

“Our new corporate headquarters will offer LGM Pharma the flexibility that we need as we expand as a company. This move represents the company we are establishing,” said Mendy Schurder, COO of LGM Pharma.

The company’s new address is 6400 Congress Avenue, Suite 1400, Boca Raton, Florida 33487.  For more information visit www.lgmpharma.com.

About LGM Pharma

LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

###

FOR IMMEDIATE RELEASE
June 27, 2011

CONTACT: Tina L. Pugliese, APR
(561) 889-3575; [email protected]

LGM Pharma Responds to Soaring Potassium Iodide Demands in the US Amid Fears of Radiation Contamination in Japan and West Coast

BOCA RATON, Florida—The latest national earthquake and consequent nuclear reactor leaks in Japan brought potassium iodide sales to the ceiling. From Fukushima, Japan to Los Angeles, California, concerned residents wasted no time in grabbing their own supply of potassium iodide which is available in the U.S. as over the counter (OTC) pills.  The pills are available as 65 mg and 130 mg doses—for child and adult, respectively. These pills have been shown to exhibit protective thyroid properties by blocking the formation of tumors caused by high radiation levels.

Quick to respond to the world’s health demands is LGM Pharma in Boca Raton, Florida. The Japan quake has firmly reiterated the company’s commitment to filling in the gaps in the supply chain of the active pharmaceutical ingredient, potassium iodide, to it’s pharmaceutical clients involved in its research, development and global distribution.

According to Mendy Schurder, Sales Director of LGM Pharma, “Though unanticipated, the sudden surge in the demand for potassium iodide pills after a nuclear disaster has not been surprising to the medical and pharmaceutical community. The UN Scientific Committee has named thyroid cancer as the Chernobyl nuclear disaster’s biggest negative health impact to the immediate community residents. In its February 2011 report, more than 6,000 residents from Belarus, Ukraine and Russia have been diagnosed with thyroid cancer as of 2006 since acquiring dangerous levels of radiation in their bodies during the time of the incident. Though the extent of the Fukushima incident is nothing like the Chernobyl disaster, that hasn’t stopped a lot of the West Coast residents from being prepared for the worst.”

About LGM Pharma

LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

###